0001845013 false 0001845013 2023-06-06 2023-06-06 0001845013...
Starton Therapeutics, Inc. (“Starton” or “the Company”), a clinical-stage biotechnology company focused on transforming standard-of-care...
Table of Contents falseQ10001845013--12-31IL 0001845013 2023-01-01 2023-03-31 0001845013 2022-01-01 2022-03-31 0001845013 2023-03-31 0001845013...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURREN...
0001845013 false 0001845013 2023-05-15 2023-05-15 0001845013...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 ...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM...
0001845013 false 0001845013 2023-04-27 2023-04-27 0001845013...
Starton’s strategic platform focuses on developing proprietary continuous delivery technology to achieve transformative patient outcomes and...
false 0001845013 0001845013 2023-03-17 2023-03-17 0001845013 hwelu:UnitsEachConsistingOfOneShareOfClassACommonStockAndOneHalfOfOneRedeemableWarra...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.